NEW YORK: World was in hope on the experimental antiviral drug ‘remdesivir’ as a treatment for coronavirus. Reports quoting a draft document that was accidentally published by the World Health Organization, says that the experimental drug failed.
Gilead Sciences, the company behind the medicine, disputed how the now-deleted post had characterized the findings, saying the data showed a “potential benefit.”
A summary of the experiment said remdesivir was “not associated with a difference in time to clinical improvement” compared to the control, according to health news site Stat, which posted a screenshot.
After a month, 13.9 percent of the patients on remdesivir had died compared to 12.8 percent of those in the control group.
A spokesman for Gilead told AFP: “We believe the post included inappropriate characterizations of the study,” saying it was terminated early due to low enrollment and was therefore not statistically meaningful.
“As such, the study results are inconclusive, though trends in the data suggest a potential benefit for remdesivir, particularly among patients treated early in the disease,” he said.